MedTrace Logo

A Study for Patients With Secondary Progressive Multiple Sclerosis

NCT00869726 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 596

Last updated 2010-06-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis.

Dirucotide is generic name for MBP8298.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

DRUG

dirucotide

500mg, intravenous, dosed once every six months for 18 months

DRUG

Placebo

intravenous, once every six months for 18 months

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Canada
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Latvia
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869726 on ClinicalTrials.gov